Ambi Inc.

Mercia Pharma, Inc.

Applied Microbiology, Inc.

The Public Health Research Institute of the City of New York, Inc.

Joslin Diabetes Center, Inc.

Peter Blackburn

June Polak

Stephen D Rubino

Sara-Ann Gusik

Stephen Grimes

Jon De La Harpe

Beth P Goldstein

Edward B Goldberg

Steven J Projan

Tihamer Orban

Debra J Cook

Vaccine compositions comprising influenza antigens formulated as nanoparticulate water in oil miniemulsions. The vaccines may be formulated at the point of use and are useful in emergency response conditions.

Adjuvanted nanoparticulate influenza vaccine

A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A&#x3b2;1-42 or an beta amyloid self epitope (e.g. A&#x3b2;1-15, or other 7-mer or 15-mer peptide epitopes derived from A&#x3b2;1-42) conjugated to an immunogenic carrier formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Immunotherapeutic compositions for the treatment of Alzheimer's disease

A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A&#x3b2;1-42 or an beta amyloid self epitope (e.g. A&#x3b2;1-15, or other 7-mer or 15-mer peptide epitopes derived from A&#x3b2;1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual &#x3b2;-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention.

Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells

Immunotherapeutic compositions for the treatment of alzheimer's disease

Immunotherapeutic compositions for the treatment of alzheimer'S disease

The invention concerns methods for killing antibiotic-resistant pathogenic bacteria responsible for disease in humans and animals. The methods employ a lanthocin such as nisin as bactericidal agent.

Method for the control of antibiotic-resistant gram positive bacteria

Lysostaphin is used to eliminate and cure staphylococcal infections including the cure of mastitis by intramammary infusion. Administration of from 2 mg to 400 mg of lysostaphin to an infected bovine mammary gland eliminates staphylococci, and the reoccurrence common with antibiotic therapy is not observed. Teat-dips containing lysostaphin, mutanolysin and lysozyme can be used as a prophylactic. Synergistic enhancement of the killing effect of lysostaphin is observed when a mild surfactant or penicillin or both is included in the formulation.

Composition for treating mastitis and other staphylococcal infections

Disclosed are compositions of nisin and GML as active ingredients for the killing of Helicobacter, as well as methods for eradicating Helicobacter colonization and treatment of Helicobacter infection which employ the GML/nisin compositions.

Compositions with activity against helicobacter

Disclosed are novel, moist paper or fabric wipes containing a bacteriocin disinfectant formulation, which have a low alcohol content and which afford rapid, one-step disinfection and drying of surfaces. Also disclosed is a method of disinfection and drying of skin, including cow teat skin, either prior to or after milking, which employs the wipes.

Moist bacteriocin disinfectant wipes and methods of using the same

The invention concerns compositions containing a lanthionine containing bacteriocin such as nisin which are stabilized by the presence of a thioether stabilizing agent against degradation.

Stabilized lanthionine bacteriocin compositions

Method for treating mastitis and other staphylococcal infections

Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Nisin compositions for use as enhanced, broad range bactericides

Compositions comprising lanthionine-containing bacteriocins such as nisin in combination with a chelator act as bactericides in low pH environments. In a preferred embodiment pharmaceutical preparations containing the compositions are used for the control of bacteria responsible for disorders of the gastrointestinal tract.

Growing community of inventors

New York, NY, United States of America

Peter Blackburn